Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTCH1 | P46531 | 3/20 | 0.63 |
| ▸ | CACNA1C | Q13936 | 8/20 | 0.59 |
| ▸ | CACNA1F | O60840 | 7/20 | 0.59 |
| ▸ | CACNA1D | Q01668 | 7/20 | 0.59 |
| ▸ | CACNA1S | Q13698 | 7/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6949497 | 0.94 | NOTCH1 (0.62) | NOTCH1CACNA1CCACNA1FCACNA1DCACNA1S | |
| SCHEMBL6952589 | 0.90 | CACNA1C (0.60) | NOTCH1CACNA1CCACNA1FCACNA1DCACNA1S | |
| SCHEMBL8092551 | 0.88 | NOTCH1 (0.56) | NOTCH1CACNA1CCACNA1FCACNA1DCACNA1S | |
| SCHEMBL6946910 | 0.85 | CACNA1C (0.67) | CACNA1CCACNA1FCACNA1DCACNA1SMEN1 | |
| SCHEMBL6949131 | 0.85 | CACNA1F (0.59) | NOTCH1CACNA1CCACNA1FCACNA1DCACNA1S | |
| SCHEMBL10745598 | 0.84 | CACNA1C (0.70) | CACNA1CCACNA1FCACNA1DCACNA1SMEN1 | |
| SCHEMBL6951602 | 0.83 | CACNA1C (0.63) | NOTCH1CACNA1CCACNA1FCACNA1DCACNA1S | |
| SCHEMBL8480212 | 0.83 | NOTCH1 (0.46) | NOTCH1CACNA1CCACNA1FCACNA1DCACNA1S | |
| SCHEMBL8790612 | 0.82 | CACNA1F (0.70) | NOTCH1CACNA1CCACNA1FCACNA1DCACNA1S | |
| SCHEMBL9153542 | 0.81 | MEN1 (0.49) | NOTCH1CACNA1CCACNA1FCACNA1DCACNA1S |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0657432-B1 | Phenyl-substituted 1,4-dihydropyridines with cerebral activity | BAYER AG (DE) | 2003-03-12 | — | — | EP | claimed |
| US-6630494-B2 | Treatment for central degenerative disorders, brain power disorders, depressions, and for prophylaxis of cerebral circulatory disorders | BAYER AKTIENGESELLSCHAFT (DE) | 2003-10-07 | — | — | US | disclosed |
| US-20010034451-A1 | Phenyl-substituted 1,4-dihydropyridines | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2001-10-25 | — | — | US | disclosed |
| US-6239155-B1 | TREATMENT OF CENTRAL DEGENERATIVE DISORDERS, AS DEMENTIAS, ALZHEIMER'S DISEASE, PARKINSON'S DISEASE OR AMYOTROPHIC LATERAL SCLEROSIS, MEMORY IMPAIRMENT, DEPRESSIONS, MIGRAINE, OF NEUROPATHIES, METABOLIC DISORDERS SUCH AS DIABETES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034451-A1 | Phenyl-substituted 1,4-dihydropyridines | GRIK4, PKM, PDK4 | NOTCH1 3293/4885CACNA1C 724/4885CACNA1F 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.